Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Senetek (SNTK) -- Ignore unavailable to you. Want to Upgrade?

To: SemiBull who wrote (33)	6/23/2003 7:50:14 PM
From: SemiBull	Read Replies (1) \| Respond to of 101

Senetek Moves to Strengthen Skincare and Dermatological Therapeutics Portfolio With Research Agreement With Czech Republic's Institute of Experimental Botany Monday June 23, 8:02 am ET NAPA, Calif., June 23 /PRNewswire-FirstCall/ -- Senetek PLC (Nasdaq: SNTK - News), (www.senetekplc.com ), a biopharmaceutical company focused on developing and co-marketing products in the key skincare/dermatological and sexual dysfunction categories worldwide, today announced it has signed a cooperative research agreement with the Institute of Experimental Botany in Prague, Czech Republic. The agreement gives Senetek exclusive access to all chemical and botanical based products and the related scientific data developed by the Institute in a broad range of skin care and dermatological therapeutics applications. Senetek has the option to enter into exclusive licenses for successful compounds for medical and cosmetic skin care application worldwide. The Institute (http://www.ueb.cas.cz/index_eng.htm ) was created in 1962 from the Department of Plant Physiology and the Department of Phytopathology of the Institute of Biology of the Czechoslovak Academy of Sciences. In 1990, it was divided into two independent units, one of which became The Institute of Experimental Botany (IEB) in Prague and Olomouc. The principal fields of scientific work in the Institute consist of plant genetics, physiology and biotechnology. In genetic research, the Institute carries out work on induced mutagenesis and DNA repair, induction of genetic variability in tissue and cell cultures in vitro, and the molecular genetics of pollen. Physiological subjects include adaptation and acclimation mechanisms of photosynthesis, hormonal and ecological control of plant growth and development, the mechanisms of action of growth regulators, physiology of plant viruses and plant pathophysiology. Prof. Brian F. C. Clark, Senetek's Chief Scientist, stated that this "cooperative research agreement broadens and strengthens Senetek's potential for discovering safe, naturally occurring compounds like kinetin with clinically demonstrable anti-ageing efficacy in human as well as plant cells." "This is a great opportunity for an academic-industrial collaboration aiming to exploit plant hormone molecules for medical and cosmetic applications," commented Professor Ivana Machackova, Director, IEB Prague. "What it means is that in cooperation with Senetek we can get closer to understanding the key regulatory mechanisms in cells more rapidly, because the same molecules that regulate cell division throughout plant ontogenesis may regulate progression through the cell cycle in humans. This approach already led to the development of roscovitine, a cell cycle drug belonging to the Cyclin-Dependent Kinase inhibitors (US pat. 6,316,456), which was licensed to Cyclacel, Dundee, U.K. and is now in Phase II trials for the treatment of breast and lung cancer and glomerulonephritis. Prof. Strnad's group has recently characterized many other molecules with anti-proliferative, anti- inflammatory and anti-senescent properties which might be useful in dermatology and skin care. The signed agreement exemplifies the Institute's long-standing objective of collaborating with world-leading skin care company like Senetek exploiting high throughput procedures to rapidly and efficiently arrive at validated medical and cosmetic use of new phytohormone-like molecules." Visit Senetek PLC's web site: senetekplc.com . Senetek PLC Investor Relations Contact: 1-707-226-3900 ext. 102 E-Mail: Pknopick@eandecommunications.com